{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'DNA vaccine', u'Nucleic acid vaccine', u'Prophylactic vaccine', u'Recombinant viral vector vaccine']}, u'DateChangeLast': u'2013-01-31T00:00:00Z', u'Countries': {u'Country': u'Uganda'}, u'Identifiers': {u'Identifier': [u'NCT00997607', u'RV 247']}, u'TitleDisplay': u'Evaluating an Ebola and a Margurg Vaccine in Uganda', u'Indications': {u'Indication': [u'Ebola virus infection', u'Marburg virus infection']}, u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Prevention', u'Randomized', u'Multiple Blind', u'Parallel Assignment']}, u'RecruitmentStatus': u'Completed', u'Teaser': u'This study would test the experimental vaccines for the <b>Ebola</b> (VRC-EBODNA023-00-VP) and Marburg (VRC-MARDNA025-00-VP) viruses, first administered separately and then together, to...injection site.Pregnant, breast-feeding, or planning to become pregnant during the first 24 weeks after enrollmentHistory of <b>Ebola</b> or Marburg virus exposureOccupational health risk of exposure to the <b>Ebola</b> or Marburg virus known to be higher than that of the general populationHas received any of the following substances...', u'DateEnd': u'2012-04-30T00:00:00Z', u'CompaniesSponsor': {u'Company': u'National Institute of Allergy and Infectious Diseases'}, u'PatientCountEnrollment': 108, u'Phase': u'Phase 1b Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': [u'DNA vaccine (im, Marburg virus infection), NIH alone', u'nucleic acid vaccine (Ebola virus infection), NIAID alone', u'DNA vaccine (im, Marburg virus infection), NIH plus nucleic acid vaccine (Ebola virus infection), NIAID']}, u'DateStart': u'2010-02-28T00:00:00Z', u'TermsPatientSelection': {u'Term': [u'Healthy volunteers accepted', u'Young Adults', u'Middle-aged Adults']}, u'@Id': u'61219', u'BiomarkerNames': {u'BiomarkerName': u'T-lymphocytes'}, u'TermsEndpoint': {u'Term': [u'Safety', u'Efficacy']}}
{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'DNA vaccine', u'Prophylactic vaccine']}, u'DateChangeLast': u'2010-08-11T00:00:00Z', u'CompaniesCollaborator': {u'Company': u'National Institutes of Health'}, u'Countries': {u'Country': u'US'}, u'Identifiers': {u'Identifier': [u'04-I-0028', u'040028', u'NCT00072605', u'VRC-204']}, u'TitleDisplay': u'Experimental ebola vaccine trial', u'Indications': {u'Indication': u'Ebola virus infection'}, u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Treatment', u'Randomized', u'Single Blind', u'Placebo Control']}, u'RecruitmentStatus': u'Completed', u'Teaser': u'...safety of an experimental vaccine (VRC-EBODNA012-00-VP) developed to protect against <b>Ebola</b> virus infection and to determine if the vaccine induces an immune response to the...Washington, DC. High rates of immune responses were observed at all dose levels. <b>Ebola</b>-specific antibody responses against at least one of the encoded antigens were detected...4000 for either GP antigen. Pseudotyped virus neutralization assay revealed that <b>Ebola</b> virus-specific neutralizing antibody was not detected in any subject. Of the two...', u'DateEnd': u'2007-08-31T00:00:00Z', u'CompaniesSponsor': {u'Company': u'National Institute of Allergy and Infectious Diseases'}, u'PatientCountEnrollment': 27, u'Phase': u'Phase 1 Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': u'VRC-EBODNA012-00-VP alone'}, u'DateStart': u'2003-10-31T00:00:00Z', u'TermsPatientSelection': {u'Term': [u'Healthy volunteers accepted', u'Young Adults']}, u'@Id': u'9023', u'BiomarkerNames': {u'BiomarkerName': [u'T-cell surface glycoprotein CD4 ', u' T-cell surface glycoprotein CD8 alpha chain']}, u'TermsEndpoint': {u'Term': [u'Safety', u'Efficacy']}}
{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'Prophylactic vaccine', u'Recombinant viral vector vaccine']}, u'DateChangeLast': u'2010-02-16T00:00:00Z', u'CompaniesCollaborator': {u'Company': u'National Institutes of Health'}, u'Countries': {u'Country': u'US'}, u'Identifiers': {u'Identifier': [u'06-I-0237', u'060237', u'NCT00374309']}, u'TitleDisplay': u'Experimental Vaccine for Prevention of Ebola Virus Infection', u'Indications': {u'Indication': u'Ebola virus infection'}, u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Prevention', u'Randomized', u'Multiple Blind', u'Placebo Control', u'Parallel Assignment']}, u'RecruitmentStatus': u'Completed', u'Teaser': u'...doses of 2 x 10(9), 2 x 10(10) and 2 x 10(11) virus particles (vp) by im injection. Secondary endpoints would be indicated by <b>Ebola</b>-specific antibody and cellular immune responses at weeks 0, 4 and 24 and Ad5 antibody titer at weeks 0, 4, and 24. Exploratory...serotype 5 antibody titers (Ad5 Ab) upto week 4. It was hypothesized that this vaccine would be safe and elicit immune responses to <b>Ebola</b>. Exploratory evaluations included immunogenicity evaluations at weeks 12, 24, and 48 and Ad5 Ab titers at week 24 and 48. A...', u'DateEnd': u'2009-05-31T00:00:00Z', u'CompaniesSponsor': {u'Company': u'National Institute of Allergy and Infectious Diseases'}, u'PatientCountEnrollment': 48, u'Phase': u'Phase 1 Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': u'Ebola virus vaccine (recombinant adenoviral vector vaccine), Crucell/NIAID alone'}, u'DateStart': u'2006-09-26T00:00:00Z', u'TermsPatientSelection': {u'Term': [u'Healthy volunteers accepted', u'Young Adults', u'Middle-aged Adults']}, u'@Id': u'9020', u'TermsEndpoint': {u'Term': [u'Safety', u'Efficacy']}}
{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'DNA vaccine', u'Prophylactic vaccine']}, u'DateChangeLast': u'2011-03-17T00:00:00Z', u'CompaniesCollaborator': {u'Company': u'National Institutes of Health'}, u'Countries': {u'Country': u'US'}, u'Identifiers': {u'Identifier': [u'08-I-0065', u'080065', u'NCT00605514']}, u'TitleDisplay': u'Ebola and Marburg Virus Vaccines', u'Indications': {u'Indication': [u'Ebola virus infection', u'Marburg virus infection']}, u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Prevention', u'Non-Randomized', u'Open Label', u'No Control', u'Parallel Assignment']}, u'RecruitmentStatus': u'Completed', u'Teaser': u'...subjects will receive the Marburg DNA vaccine and Group 2 subjects will receive the <b>Ebola</b> DNA WT vaccine. The first 3 enrollments in each group will occur no faster than one...Before the initiation of Group 2, the FDA must have assessed administration of the <b>Ebola</b> DNA WT vaccine as safe to proceed. In addition, there will be a study pause with...dose 4 mg and Day 56 plus or minus 7 with a dose 4 mg. VRC 206 Group 2 will receive <b>Ebola</b> DNA WT, accrue 10 subjects and deliver injections on Day 0 with a dose of 4 mg, Day...', u'DateEnd': u'2010-06-30T00:00:00Z', u'CompaniesSponsor': {u'Company': u'National Institute of Allergy and Infectious Diseases'}, u'PatientCountEnrollment': 20, u'Phase': u'Phase 1 Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': u'DNA vaccine (im, Marburg virus infection), NIH alone'}, u'DateStart': u'2008-01-31T00:00:00Z', u'TermsPatientSelection': {u'Term': [u'Young Adults', u'Middle-aged Adults']}, u'@Id': u'11465', u'TermsEndpoint': {u'Term': [u'Safety', u'Efficacy']}}
{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'Prophylactic vaccine', u'Recombinant viral vector vaccine']}, u'DateChangeLast': u'2012-01-20T00:00:00Z', u'CompaniesCollaborator': {u'Company': u'National Institute of Allergy and Infectious Diseases'}, u'DateStart': u'2010-04-06T00:00:00Z', u'TitleDisplay': u'A phase I, safety and immunogencity study of an Ebola/Marburg virus vaccine', u'Indications': {u'Indication': [u'Ebola virus infection', u'Marburg virus infection']}, u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Treatment']}, u'RecruitmentStatus': u'Completed', u'Teaser': u'The vaccine was found to be safe and immunogenic [1092813]. This was a phase I, safety and immunogencity study of an <b>Ebola</b>/Marburg virus vaccine [1092813]. By April 2010, the trial had been completed [1092813].', u'DateEnd': u'2010-04-06T00:00:00Z', u'CompaniesSponsor': {u'Company': u'Crucell NV'}, u'Phase': u'Phase 1 Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': u'Ebola/Marburg vaccine (AdVac, PER.C6), Crucell/NIAID alone'}, u'@Id': u'65870', u'TermsEndpoint': {u'Term': [u'Safety', u'Efficacy']}}
{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'Antisense oligonucleotide inhibitor', u'Antiviral']}, u'DateChangeLast': u'2012-07-13T00:00:00Z', u'Identifiers': {u'Identifier': [u'6002-us-101', u'NCT01353027']}, u'CompaniesCollaborator': {u'Company': u'US Department of Defense'}, u'Countries': {u'Country': u'US'}, u'ActionsPrimaryInterventionsPrimary': {u'Action': u'VP24 gene inhibitor'}, u'TitleDisplay': u'Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus', u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Treatment', u'Randomized', u'Multiple Blind', u'Placebo Control', u'Parallel Assignment']}, u'RecruitmentStatus': u'Completed', u'Teaser': u'...total elimination and 30.7 of AVI-7539 elimination [1274750], [1276835]. The purpose of this study was to characterize the safety, tolerability and pharmacokinetics of single administration of AVI-6002, a post-exposure prophylaxis candidate treatment for <b>Ebola</b> virus, in healthy human subjects.In October 2011, an independent data and safety monitoring board (DSMB) recommended the study progress to the next highest dosing level after no safety concerns were identified from five cohorts [1232439].In February 2012...', u'IndicationsAdverse': {u'Indication': [u'Dermatological disease', u'Fatigue', u'Gastrointestinal disease', u'Headache', u'Nausea', u'Respiratory disorder']}, u'DateEnd': u'2011-11-30T00:00:00Z', u'CompaniesSponsor': {u'Company': u'Sarepta Therapeutics Inc'}, u'PatientCountEnrollment': 30, u'Phase': u'Phase 1 Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': u'AVI-7537 alone'}, u'DateStart': u'2010-05-31T00:00:00Z', u'TermsPatientSelection': {u'Term': [u'Healthy volunteers only', u'Young Adults', u'Middle-aged Adults']}, u'@Id': u'77351', u'TermsEndpoint': {u'Term': [u'Safety', u'Pharmacokinetics']}}
{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'Anticancer', u'Antiviral', u'Coagulation inhibitor', u'Fibrinolysis stimulator']}, u'DateChangeLast': u'2009-05-19T00:00:00Z', u'Countries': {u'Country': u'UK'}, u'ActionsPrimaryInterventionsPrimary': {u'Action': u'Factor VII antagonist'}, u'TitleDisplay': u'A phase Ia, single-center, double-blind, randomized, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of rNAPc2 in healthy male volunteers', u'Indications': {u'Indication': [u'Angina', u'Cancer', u'Cardiovascular disease', u'Deep vein thrombosis', u'Ebola virus infection', u'Myocardial infarction', u'Thrombosis', u'Unstable angina']}, u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Treatment', u'Randomized', u'Multiple Blind', u'Placebo Control']}, u'RecruitmentStatus': u'Completed', u'Teaser': u'This phase Ia, single-center, double-blind, randomized, placebo-controlled study was designed to evaluate the safety, pharmacokinetics and efficacy of rNAPc2 in healthy male volunteers [266827], [264179].', u'CompaniesSponsor': {u'Company': u'Dendreon San Diego LLC'}, u'PatientCountEnrollment': 30, u'Phase': u'Phase 1a Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': u'rNAPc2 alone'}, u'DateStart': u'1997-04-30T00:00:00Z', u'TermsPatientSelection': {u'Term': [u'Healthy volunteers accepted', u'Male']}, u'@Id': u'55425', u'TermsEndpoint': {u'Term': [u'Safety', u'Efficacy', u'Pharmacokinetics']}}
{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'Anti-inflammatory', u'Antihypertensive', u'Antiviral', u'Vulnerary agent']}, u'DateChangeLast': u'2010-09-21T00:00:00Z', u'Countries': {u'Country': u'UK'}, u'ActionsPrimaryInterventionsPrimary': {u'Action': u'Antithrombin III'}, u'TitleDisplay': u'A phase I, safety study of AT-III in healthy male volunteers', u'Indications': {u'Indication': [u'Ebola virus infection', u'Marburg virus infection', u'Sepsis', u'Skin burns', u'Thrombosis']}, u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Treatment']}, u'RecruitmentStatus': u'Status not specified', u'Teaser': u'A phase I, safety study of AT-III in healthy male volunteers [223347], [227738].', u'CompaniesSponsor': {u'Company': u'Guys Drug Research Unit'}, u'PatientCountEnrollment': 20, u'Phase': u'Phase 1 Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': u'antithrombin alfa alone'}, u'DateStart': u'1996-10-21T00:00:00Z', u'TermsPatientSelection': {u'Term': [u'Healthy volunteers accepted', u'Male', u'Young Adults']}, u'@Id': u'52666', u'TermsEndpoint': {u'Term': u'Safety'}}
{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'Antiviral', u'Unspecified drug target', u'siRNA agent']}, u'DateChangeLast': u'2014-03-10T00:00:00Z', u'CompaniesCollaborator': {u'Company': u'US Department of Defense'}, u'Countries': {u'Country': u'US'}, u'Identifiers': {u'Identifier': [u'NCT01518881', u'TKM-EBOV-001']}, u'TitleDisplay': u'Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion', u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Treatment', u'Randomized', u'Single Blind', u'Placebo Control', u'Parallel Assignment']}, u'RecruitmentStatus': u'Recruiting', u'Teaser': u'...would have up to six cohorts with four subjects (three receiving TKM-100201 [TKM-<b>Ebola</b>] and one receiving saline placebo) in each cohort. Additional cohorts might be enrolled...the study would have up to three cohorts with four subjects (three receiving TKM-<b>Ebola</b> and one receiving saline placebo) in each cohort. Additional cohorts might be enrolled...within 30 days of screening (as determined by the investigator[s])Reports a history of <b>Ebola</b> virus exposureReports an occupational health risk of exposure to <b>Ebola</b> virus known...', u'DateEnd': u'2012-08-31T00:00:00Z', u'CompaniesSponsor': {u'Company': u'Tekmira Pharmaceuticals Corp'}, u'PatientCountEnrollment': 24, u'Phase': u'Phase 1 Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': u'TKM-Ebola alone'}, u'DateStart': u'2012-01-31T00:00:00Z', u'TermsPatientSelection': {u'Term': [u'Healthy volunteers only', u'Young Adults', u'Middle-aged Adults']}, u'@Id': u'84326', u'TermsEndpoint': {u'Term': [u'Safety', u'Pharmacokinetics']}}
{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'Antiviral', u'Unspecified drug target', u'siRNA agent']}, u'DateChangeLast': u'2014-01-30T00:00:00Z', u'CompaniesCollaborator': {u'Company': u'US Department of Defense'}, u'Countries': {u'Country': u'US'}, u'Identifiers': {u'Identifier': [u'NCT02041715', u'TKM-EBOV-002']}, u'TitleDisplay': u'Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous TKM-100802', u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Treatment', u'Randomized', u'Single Blind', u'Placebo Control', u'Parallel Assignment']}, u'RecruitmentStatus': u'Recruiting', u'Teaser': u'...demonstrates a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibodyReports infections requiring antibiotic therapy within 28 days of screening (as determined by the PI)Reports a history of <b>Ebola</b> virus exposureReports an occupational health risk of exposure to <b>Ebola</b> virus known to be higher than that of the general populationReports a known or suspected hypersensitivity or previous severe reactions to any of the constituents of the TKM-100802 including oligonucleotide- or lipid-based...', u'DateEnd': u'2014-07-31T00:00:00Z', u'CompaniesSponsor': {u'Company': u'Tekmira Pharmaceuticals Corp'}, u'PatientCountEnrollment': 28, u'Phase': u'Phase 1 Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': u'TKM-Ebola alone'}, u'DateStart': u'2014-01-31T00:00:00Z', u'TermsPatientSelection': {u'Term': [u'Healthy volunteers only', u'Young Adults', u'Middle-aged Adults']}, u'@Id': u'168906', u'TermsEndpoint': {u'Term': [u'Safety', u'Pharmacokinetics']}}
{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'Anticancer', u'Antiviral', u'Coagulation inhibitor', u'Fibrinolysis stimulator']}, u'DateChangeLast': u'2009-05-19T00:00:00Z', u'DateStart': u'2001-12-31T00:00:00Z', u'ActionsPrimaryInterventionsPrimary': {u'Action': u'Factor VII antagonist'}, u'TitleDisplay': u'A phase I, randomized, placebo-controlled, double-blind, multiple-period crossover study to investigate the potential of recombinant factor VIIa (rVIIa) to induce thrombin generation in healthy subjects pretreated with rNAPc2', u'Indications': {u'Indication': [u'Angina', u'Cancer', u'Cardiovascular disease', u'Deep vein thrombosis', u'Ebola virus infection', u'Myocardial infarction', u'Thrombosis', u'Unstable angina']}, u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Treatment', u'Randomized', u'Multiple Blind', u'Placebo Control', u'Crossover Assignment']}, u'RecruitmentStatus': u'Status not specified', u'Teaser': u'This phase I, randomized, placebo-controlled, double-blind, multiple-period crossover study was designed to investigate the potential of recombinant factor VIIa (rVIIa) to induce thrombin generation in healthy subjects pretreated with rNAPc2 [492192], [492284].', u'CompaniesSponsor': {u'Company': u'Dendreon San Diego LLC'}, u'PatientCountEnrollment': 6, u'Phase': u'Phase 1 Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': u'rNAPc2 plus rVIIa'}, u'TermsPatientSelection': {u'Term': u'Healthy volunteers accepted'}, u'@Id': u'55458', u'TermsEndpoint': {u'Term': u'Efficacy'}}
{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'Anticancer', u'Antiviral', u'Coagulation inhibitor', u'Fibrinolysis stimulator']}, u'DateChangeLast': u'2009-05-19T00:00:00Z', u'DateStart': u'2002-12-31T00:00:00Z', u'ActionsPrimaryInterventionsPrimary': {u'Action': u'Factor VII antagonist'}, u'TitleDisplay': u'A phase I study to evaluate the safety, pharmacodynamics and pharmacokinetics of rNAPc2 in healthy volunteers', u'Indications': {u'Indication': [u'Angina', u'Cancer', u'Cardiovascular disease', u'Deep vein thrombosis', u'Ebola virus infection', u'Thrombosis', u'Unstable angina']}, u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Treatment']}, u'RecruitmentStatus': u'Status not specified', u'Teaser': u'This phase I study was designed to evaluate the safety, pharmacodynamics and pharmacokinetics of rNAPc2 in healthy volunteers [473059].', u'CompaniesSponsor': {u'Company': u'Dendreon San Diego LLC'}, u'Phase': u'Phase 1 Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': u'rNAPc2 alone'}, u'TermsPatientSelection': {u'Term': u'Healthy volunteers accepted'}, u'@Id': u'55450', u'TermsEndpoint': {u'Term': [u'Safety', u'Pharmacokinetics', u'Pharmacodynamics']}}
{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'Anticancer', u'Antiviral', u'Coagulation inhibitor', u'Fibrinolysis stimulator']}, u'DateChangeLast': u'2009-05-19T00:00:00Z', u'Countries': {u'Country': u'US'}, u'ActionsPrimaryInterventionsPrimary': {u'Action': u'Factor VII antagonist'}, u'TitleDisplay': u'A phase I, randomized, dose-escalation, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of rNAPc2 in healthy male volunteers', u'Indications': {u'Indication': [u'Angina', u'Cancer', u'Cardiovascular disease', u'Deep vein thrombosis', u'Ebola virus infection', u'Myocardial infarction', u'Thrombosis', u'Unstable angina']}, u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Treatment', u'Randomized', u'Multiple Blind', u'Placebo Control']}, u'RecruitmentStatus': u'Completed', u'Teaser': u'This phase I, randomized, dose-escalation, double-blind, placebo-controlled study was designed to evaluate the safety, pharmacokinetics and efficacy of rNAPc2 in healthy male volunteers [287149], [317563].', u'CompaniesSponsor': {u'Company': u'Dendreon San Diego LLC'}, u'Phase': u'Phase 1 Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': u'rNAPc2 alone'}, u'DateStart': u'1998-05-13T00:00:00Z', u'TermsPatientSelection': {u'Term': [u'Healthy volunteers accepted', u'Male']}, u'@Id': u'55444', u'TermsEndpoint': {u'Term': [u'Safety', u'Efficacy', u'Pharmacokinetics']}}
{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'Antisense oligonucleotide inhibitor', u'Antiviral']}, u'DateChangeLast': u'2013-01-25T00:00:00Z', u'Identifiers': {u'Identifier': [u'7537-us-101', u'NCT01593072', u'W9113M-10-C-0056']}, u'CompaniesCollaborator': {u'Company': u'US Department of Defense'}, u'Countries': {u'Country': u'US'}, u'ActionsPrimaryInterventionsPrimary': {u'Action': u'VP24 gene inhibitor'}, u'TitleDisplay': u'A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers', u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Treatment', u'Randomized', u'Multiple Blind', u'Placebo Control', u'Parallel Assignment']}, u'RecruitmentStatus': u'Terminated', u'Teaser': u'The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of AVI-7537 compared to matched placebo in healthy male and female subjects.', u'DateEnd': u'2013-01-31T00:00:00Z', u'CompaniesSponsor': {u'Company': u'Sarepta Therapeutics Inc'}, u'Phase': u'Phase 1 Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': u'AVI-7537 alone'}, u'DateStart': u'2012-08-31T00:00:00Z', u'TermsPatientSelection': {u'Term': [u'Healthy volunteers only', u'Young Adults', u'Middle-aged Adults']}, u'@Id': u'87199', u'TermsEndpoint': {u'Term': [u'Safety', u'Pharmacokinetics']}}
{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'Immunomodulator', u'Prophylactic vaccine', u'Protein subunit vaccine', u'Recombinant viral vector vaccine']}, u'DateChangeLast': u'2013-12-02T00:00:00Z', u'Identifiers': {u'Identifier': [11669, u'HVTN 090', u'NCT01438606']}, u'Countries': {u'Country': u'US'}, u'PatientSegmentTerms': {u'PatientSegment': [u'HIV Vaccine - HIV Seronegative Subjects', u'HIV infection - Subjects at Risk of Developing HIV Infection']}, u'ActionsPrimaryInterventionsPrimary': {u'Action': u'HIV GAG protein modulator'}, u'TitleDisplay': u'Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults', u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Prevention', u'Randomized', u'Multiple Blind', u'Placebo Control', u'Parallel Assignment']}, u'RecruitmentStatus': u'Completed', u'Teaser': u'The purpose of this placebo-controlled, dose-escalation study was to evaluate the safety and immune response to a rVSVIN HIV-1 gag vaccine in HIV-uninfected subjects. Study researchers would also determine the maximum dose of the vaccine that participants can safely receive.By December 2011, 20 subjects had been immunized [1252290].By May 2012, 51 subjects had been vaccinated without any safety concerns [1286555].By September 2013, study was completed [1480508].', u'IndicationsAdverse': {u'Indication': [u'Chill', u'Fever', u'Headache', u'Lymphadenopathy', u'Mouth ulcer', u'Neutropenia']}, u'CompaniesSponsor': {u'Company': u'National Institute of Allergy and Infectious Diseases'}, u'PatientCountEnrollment': 60, u'Phase': u'Phase 1 Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': u'rVSVIN HIV-1 gag vaccine, Profectus Biosciences alone'}, u'DateStart': u'2011-10-31T00:00:00Z', u'TermsPatientSelection': {u'Term': [u'Healthy volunteers only', u'Young Adults', u'Middle-aged Adults']}, u'@Id': u'81125', u'BiomarkerNames': {u'BiomarkerName': [u'Alanine transaminase ', u' Alkaline phosphatase ', u' Aspartate aminotransferase ', u' Creatinine ', u' Hemoglobin ', u' Interferon gamma ', u' Interleukin-2 ', u' T-cell surface glycoprotein CD4 ', u' T-cell surface glycoprotein CD8 alpha chain']}, u'TermsEndpoint': {u'Term': [u'Safety', u'Efficacy']}}
{u'ActionsSecondaryInterventionsPrimary': {u'Action': [u'Antisense oligonucleotide inhibitor', u'Antiviral']}, u'DateChangeLast': u'2013-03-13T00:00:00Z', u'Identifiers': {u'Identifier': [u'6003-us-101', u'NCT01353040', u'W9113M-10-C-0056']}, u'CompaniesCollaborator': {u'Company': u'US Department of Defense'}, u'Countries': {u'Country': u'US'}, u'ActionsPrimaryInterventionsPrimary': {u'Action': u'VP24 gene inhibitor'}, u'TitleDisplay': u'Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Marburg Virus', u'PrimaryCompletionDate': u'', u'TermsDesign': {u'Term': [u'Interventional', u'Treatment', u'Randomized', u'Multiple Blind', u'Placebo Control', u'Parallel Assignment']}, u'RecruitmentStatus': u'Completed', u'Teaser': u'The purpose of this study was to characterize the safety and pharmacology of single iv administration of AVI-6003 (PMOplus), a post-exposure prophylaxis candidate treatment for Marburg virus.In October 2011, independent Data and Safety Monitoring Board recommended the study to progress to the next highest dosing level (9 mg/kg) after no safety concerns were identified from five cohorts [1232439], [1232679], [1229947]. In October 2011, dosing of the first subject was started [1232679]. In February 2012, the DSMB suggested the study to progress to multiple ascending dose as no safety concerns were identified from six cohorts (n = 30) [1261544].', u'IndicationsAdverse': {u'Indication': [u'Anxiety disorder', u'Fatigue', u'Gastrointestinal disease', u'Headache', u'Inflammatory disease', u'Respiratory disorder', u'Tremor']}, u'DateEnd': u'2011-12-31T00:00:00Z', u'CompaniesSponsor': {u'Company': u'Sarepta Therapeutics Inc'}, u'PatientCountEnrollment': 30, u'Phase': u'Phase 1 Clinical', u'InterventionsPrimaryDisplay': {u'Intervention': u'AVI-7288 alone'}, u'DateStart': u'2011-05-31T00:00:00Z', u'TermsPatientSelection': {u'Term': [u'Healthy volunteers only', u'Young Adults', u'Middle-aged Adults']}, u'@Id': u'77350', u'TermsEndpoint': {u'Term': [u'Safety', u'Pharmacokinetics']}}
